Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Efficacy and Safety of BGB-3111 in Participants With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Diagnostic report had to include evidence for morphological and cyclin D1 or t (11; 14).~2. Eastern Cooperative Oncology Group performance status of 0-2.~3. Measurable disease by computed tomography/magnetic resonance imaging.~4. Received prior regimens for MCL.~5. Documented failure to achieve any response, (stable disease or progressive disease during treatment) or documented progressive disease after response to the most recent treatment regimen.~6. Aspartate aminotransferase and alanine aminotransferase ≤ 2.5 x upper limit of normal (ULN).~7. Total bilirubin ≤ 2 x ULN (unless documented Gilbert's syndrome).~8. Life expectancy of \> 4 months.~Key Exclusion Criteria:~1. Current or history of central nervous system lymphoma.~2. Prior exposure to a BTK inhibitor before enrollment.~3. Prior corticosteroids with anti-neoplastic intent within 7 days.~4. Major surgery within 4 weeks of screening.~5. Toxicity must have recovered from prior chemotherapy.~6. History of other active malignancies within 2 years of study entry.~7. Currently clinically significant active cardiovascular disease.~8. QT interval corrected with Fridericia's formula \> 450 microseconds or other significant electrocardiogram abnormalities.~9. Uncontrolled systemic infection or infection requiring parenteral anti-microbial therapy.~10. Known human immunodeficiency virus infection, or active hepatitis B or hepatitis C infection (detected positive by polymerase chain reaction).~Note: Other protocol-defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Zanubrutinib (Type: EXPERIMENTAL): Zanubrutinib (160 milligrams) administered orally twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).